Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29863302 | 0.89 | NPC1 (0.50) | MAPTBCL2L1BADNPC1MAPK13 | |
| SCHEMBL98299 | 0.89 | NPC1 (0.50) | MAPTBCL2L1BADNPC1MAPK13 | |
| SCHEMBL8523665 | 0.80 | MAPT (0.55) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL3340538 | 0.79 | AHR (0.48) | CRBNPARP1AHRPDK2 | |
| SCHEMBL30463280 | 0.79 | AHR (0.48) | CRBNPARP1AHRPDK2 | |
| SCHEMBL427457 | 0.79 | MAPT (0.53) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL2408663 | 0.79 | MAPT (0.53) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL20777507 | 0.78 | BCL2L1 (0.45) | BCL2L1BADPARP1 | |
| SCHEMBL20597191 | 0.77 | CREBBP (0.38) | MAPTNPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL22368762 | 0.75 | MAPT (0.49) | MAPTNPC1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BIOPORT R&D, INC. | 2005-10-20 | — | — | US | disclosed |
| US-6130217-A | ANTITUMOR | PFIZER INC (US) | 2000-10-10 | — | — | US | disclosed |
| US-4340595-A | ADRENERGIC BLOCKING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1982-07-20 | — | — | US | disclosed |
| US-4340595-A | ADRENERGIC BLOCKING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1982-07-20 | — | — | US | disclosed |
| EP-0011747-B1 | AMINOPROPANOL DERIVATIVES OF 6-HYDROXY-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0011747-B1 | AMINOPROPANOL DERIVATIVES OF 6-HYDROXY-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1982-05-19 | — | — | EP | disclosed |
| EP-0011747-A1 | Aminopropanol derivatives of 6-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-2-ones, process for their preparation, and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1980-06-11 | — | — | EP | disclosed |
| EP-0011747-A1 | Aminopropanol derivatives of 6-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-2-ones, process for their preparation, and pharmaceutical compositions containing them | BASF Aktiengesellschaft (DE) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BAK1, BAD, BAX | MAPT 2956/4885BCL2L1 10/4885BAD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.